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Group A streptococcal infection is being implicated in the formation of movement disorders such 
as PANDAS, Tourette syndrome, Sydenham's chorea , and general tics. It is suggested that 
antibodies produced against the conservative region of streptococcal M proteins are cross-
reacting with neuronal tissue in an autoimmune response. One area of proposed cross-
reactivity within the brain is the basal ganglia, the center for movement regulation. Antibodies 
against this region are called anti-basal ganglia antibodies. Monoclonal mouse antibody 10F5 
(mAb1 OF5) is a streptococcal M6 antibody. Previous studies in our laboratory, using in vitro 
techniques, demonstrated that mAb10F5 bound in the basal ganglia of Lewis rats and has 
antiphospholipid properties. The current study sought to examine the interaction of mAb10F5 in 
Lewis rat brains in vivo. Rats were injected with either mAb10F5 or a positive control, myosin 
(type II) antibody, and euthanized after 24, 48, or 72 hours. Slices from the rostral and 
mid rostral sections of these brains along with those of uninjected controls were analyzed using 
immunofluorescence and fluorescent microscopy. The caudate and putamen (CPu). a part of 
the basal ganglia , was significantly positive compared to controls at 24, 48, and 72 hours in the 
mAb1 OF5 treated group and at 24 and 48 hours in the myosin (type II) antibody treated group. 
II was discerned that in the mAb10F5 group the antibody crossed the blood-brain-barrier at 24 
hours and remained in the CPu through 72 hours. The myosin (type II) antibody did not cross 
the blood-brain-barrier until 48 hours, and was no longer Significantly in the CPu after 72 hours. 
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Background 
Group A streptococcal infections are commonly known to cause pharyngitis , impedigo, 
streptococcal toxic shock syndrome, necrotizing fasciitis, and septicemia (Cunningham 2000). 
Other sequelea now also being associated with group A streptococcal infection are acute 
rheumatic fever and a number of movement disorders such as Tourette syndrome, tics, 
pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection 
(PANDAS), and Sydenham's chorea (Husby et. a!. 1976, Rizzo et. al. 2006. Swedo e1. a!. 1998, 
Kirvan et. al. 2003). 
The emergence of neurological disorders such as PANDAS, Tourette syndrome, and 
Sydenham's chorea has been observed in patients weeks to months after streptococcal 
infection (Dale 2003, Sweda et al 1998). Tourette syndrome is described as having chronic 
multiple motor tics and one or more vocal tics, which may be episodic (American Psychiatric 
Association 2000, Rizzo et a1. 2006). In comparison , PANDAS is characterized by the sudden 
appearance or exacerbation of tics or obsessive-compulsive disorder in 3-11 year aids following 
a group A streptococcal infection (Pavone et al. 2006. Swedo et al. 1998). These 
neuropsychiatric disorders, along with general tics, are in some cases thought to be caused by 
an autoimmune response to group A streptococcal infection (Dale 2003). 
The cell membrane of group A streptococcus has M proteins attached to it which extend 
out -50nm as alpha-helical coiled-coil dimers and are the bacteria's major virulence factor 
(Cunningham 2000, Jones et a1.1988, Phillipes et al. 1981). The M protein contains amino acid 
repeat regions A, 8 , and C. The A repeat region is near the N terminus while the C region is 
closer to the carboxy-terminus (Bessin 1989). Regions near the N terminus are more vaned. 
while sequences in the C region are conserved between M protein subtypes (Jones et aL 1988). 
More than 80 subtypes of st,"eptococcal M protein have been identified (Cunningham 2000). 
These M protein subtypes have been divided into classes depending on their reactivity with 
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antibodies against the C repeat region. Class I M proteins contain epitopes within the C repeat 
region which react with M protein antibodies (Cunningham 2000, Bessin 1989). 
The autoimmune activity thought to cause neurological disorders is explained by 
antibodies against several M proteins including the M6 protein, a class I M protein, of group A 
streptococcus displaying molecular mimicry. Certain M6 antibodies recognize the GLRRO 
sequence in the conserved C region of the M protein and cross-react with body tissues (Jones 
et a!. 1986). Group A streptococcal antigens have been found to cross-react with a variety of 
mammalian tissues including cardiac and skeletal muscles, valvular tissue, kidney, skin, and 
neuronal tissues (Zabriskie 1967). In particular, M6 proteins have been shown to induce cross-
reactive antibodies against neuronal tissues in rats (Dale 2003). 
The presence of anti-brain antibodies is the most observed immunologic abnormality in 
patients with autoimmune neuropsychiatric disorders associated with group A streptococcal 
infection (Martino et a!. 2004). Specifically, M6 antibodies have been found to cross-react with 
proteins in the basal ganglia more intensely than in cerebellar or cortical tissue (Bronze et al. 
1993). 
The basal ganglia is composed of the caudate and putamen (together the striatum), 
globus pallidus. subthalamus, and substantia nigra. After receiving information from the 
cerebral cortex, the basal ganglia facilitates wanted movement while inhibiting unwanted 
movement (Mink 2003). In the movement pathway, the caudate and putamen are normally 
silent while the globus pallidus sends signals to the thalamus to prevent movement. When a 
signal arrives from the cortex to the caudate and putamen it overrides the inhibition of the 
globus pallidus by ending the inhibitory signal. Antibodies against the basal ganglia are called 
anti-basal ganglia antibodies. Anti-basal ganglia antibodies have be found in patients With 
Tourette syndrome, obsessive-compulsive disorder, Sydenham's chorea, and PANDAS (Church 
et al. 2004, Rizzo el al. 2006, Singer et a!. 2004, Trifiledi et al. 1999). In a study by Rizzo ei al. , 
antistreptococcal antibodies were found in 18 of 22 (82%) of Tourette syndrome patients with 
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anti-basal ganglia antibodies (Rizzo et aL 2006). Brain imaging, including volumetric studies, 
during the acute phase of PANDAS have distinctly shown an enlargement of the caudate and 
putamen (Dale 2003, Giedd et al. 2000, Peterson et al. 2000). 
Monoclonal mouse antibody 10F5 (mAb10F5) is a group A streptococcal M serotype 
against M6 proteins (Jones et al. 1986). This serotype reacts with an epitope in the alpha-
helical conserved region of the M6 protein (Jones et al. 1986, Jones et al. 1988). It is suspected 
of interacting with myosin in cardiac and brain tissue. Previous in vitro research in our lab has 
dem onstra ted th at mAb 1 0 F 5 has a ntiphosp hoi i pid cha racle ri 5 tics . Th is resea rch a I so fou n d that 
in vitro mAb10F5 bound in regions of the basal ganglia, especially the caudate and putamen, in 
Lewis rats. The current study expanded upon our previous research and observes in vivo brain 
binding of mAb10F5 in Lewis rats. 
Methods 
The Lewis rat is the current animal model for streptococcal research (Li et al. 2004). 
Because of this, Lewis rats from our physiology colony were used. The rats were 9-12 months 
in age due to availability. Female Lewis rats were used since their lower weights would require 
the use of less antibody. The rats were kept in rectangular cages with wire lids, in groups of 2-
3. They were kept on a twelve-hour tighUdark cycle , and given constant access to chow (18% 
protein rodent diet) and water. 
A total of 15 rats were used . The experimental group, injected with mAb1 OF5, and the 
experimental control group, injected with myosin type 11 antibody, each contained six rats. 
Three lime points were examined (24 , 48, and 72 hours), with two experimental animals and 
two experimental control animals per time point. The remaining three rats were used as 
uninjected negative controls. 
A blood sample was taken from the rats prior to an tibody injection zero time pOint) and 
just before euthanization. This was done by first placing the rat in a restraining tube on a low 
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temperature heating pad. The rat was allowed to warm for approximately ten minutes to 
increase blood flow. The tip of the tail was cleaned and clipped with a razor blade. The tail was 
milked to obtain approximately 1ml of blood in a 1.3ml L-Heparin blood collection tube. The 
blood collection tube was kept on ice during this entire process. Once the blood was collected, 
bleeding was stopped by applying pressure. The blood sample was left on ice for 30-60 
minutes as specified by the tube directions. It was then spun for 5 minutes at 1700rpm and 4·C 
in a refrigerated centrifuge. A pipette was used to remove the separated plasma and put it into 
a microcentrifuge tube. Blood and plasma samples were stored in a -80T freezer for future 
immunoassays if necessary. 
Rats were then weighed . Their individual average weights were recorded and used to 
determine their blood volume with an online blood volume calculator. Both mAb10F5 and the 
positive control myosin (Type II) antibody were administered at a 1 :200 dose. The necessary 
amount of antibody was calculated using the blood volume. Antibody injections never exceeded 
O.1m\. 
The monoclonal mouse antibody 10F5 was supplied by Vincent Fischetti's laboratory. 
The myosin (type II) antibody was ordered from AbO Serotec. Each antibody was resuspended 
in sterile saline. This was done by first adding 400IJI milli-Q water to the insert cup of an 
ultrafree-MC microcenlrifuge filter and centrifuging it for 20 minutes at 2000xg and 22'C. The 
water was removed from both the insert cup and the bottom waste tube. The calculated amount 
of antibody was then added to the insert cup and centrifuged for 20 minutes at 2000xg and 
22 'C. The waste from the bottom tube was then removed, 50)JI of sterile saline was added to 
the insert cup, and the filtering tube was centrifuged again for 20 minutes at 2000xg and 22' C 
This step was repeated three times by adding 50iJi again, then 301J\, and finally 30)JI again of 
sterile saline. The remaining solution in the insert cup was brought back up to the original 
volume of antibody added using s erile saline . 
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For the injection of the antibody the rat was placed in a restraining tube. A tail vein was 
found and the area above it was cleaned . The calculated amount of antibody was injected into 
the tail vein using a 1 ml syringe. 
The rats were euthanized 24.48, or 72 hours after injection. This was done by the 
physiology animal caretaker using carbon dioxide and a thoracotomy. The heads were then 
removed using a guillotine. The cerebrum was removed, rinsed with 1x phosphate buffer 
solution (PBS), and stored in 4% parafomaldehyde at -4°C. 
For analysis, the brain was sliced using a licor vibratome. To do this, the brain was first 
coronally quartered using a razor blade. Only the rostral and midrostral quarters were 
examined. The remaining caudal half of the brain was stored in 4% paraformaldehyde at -4°C 
for future observation. The quarter being sliced was attached to the slicing plate using 
superglue and then covered with PBS. Six to seven 90IJm slices were obtained and placed in 
the wells of a 24 well non-culture treated plate with 500IJ1 PBS. The remainder of the brain was 
once again stored in 4% parafomaldehyde at -4 cG. 
The brain slices were next prepared for immunofluorescence, First, the PBS was 
removed from the wells, 500IJI of PBS with OS'Io Triton X-100 was added, and the plate was set 
to rock for 30 minutes. Second, the solution was removed and the slices were washed for ten 
minutes with 5001-11 1 x PBS. This wash was repeated two more times. The third wash was then 
removed, 200IJ1 of Odyssee blocking buffer was added to the wells, and the plate was set to 
rock for 30 minutes . A solution containing 250~1 10x PBS, 2500}J1 milli-Q water, 7501J1 Odyssee 
blocking buffer, and 2. 71 ~I anti-mouse Alexa Fluor 488 was made. Of this, 300IJI was added to 
the wells and set to rock in the dark for 90 minutes. The solution was then removed and the 
slices were washed for ten minutes with 5001-11 1 x PBS. This wash was repeated two more 
times. The PBS was removed from three of the wells, and the slices were covered with sudan 
black to decrease background fiuorescencc. This was set to rock for 30 minu es , then removed, 
and the slices were washed with 5001-11 of 1 x PBS. The entire preparation for 
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immunofluorescence was repeated using anti-mouse Alexa Fluor 350 on one slice from each 
quarter of the mAb1 OF5 brains, and anti-mouse Alexa Fluor 568 on one slice from each quarter 
of the positive control myosin (type II) and negative control brains. The second type of Alexa 
Fluor was used to eliminate false positives. 
Brain slices were imaged using a Carl Zeiss fluorescent microscope with 5 and 'to x 0.25 
NA CP-Achromat objectives. A Sony cybershot camera attached to the microscope was used 
to obtain fluorescent images of various regions including parts of the basal ganglia, the 
hippocampus, and the cortex. Image-Pro Express 6.0 was used to acquire fluorescent 
histograms with a range of 0-255 . Fluorescence levels for each antibody were compared to the 
controls across the time pOints. A single factor ANOVA was used to find the significance 
(p<.05) of the data compared to control levels. 
Results 
In the rat brain, the caudate and putamen are combined to form the CPu. In the 
mid rostral quarter, higher levels of fluorescence were observed in the CPu of both the mAb10F5 
and the positive control myosin (type II) antibody treated rats compared to the uninjected 
negative controls (Figure 1). The uninjected controls had an average fluorescence of 62.81 on 
a scale ranging from 0-255 (Table 1). When compared to controls, at 24 hours mAb10F5 CPu 
had an average fluorescence of 124.02 and a p-value of 0.00437, while myosin (type II) 
antibody CPu had an average fluorescence of 95.09 and a p-value of 0.03953. At 48 hours, 
mAb1 OF5 CPu had an average fluorescence of 132.25 and a p-value of 0.00044, while myosin 
(Iype II) antibody CPu had an average fluorescence of 153.55 and a p-value of 0.00040. At 72 
hours, mAb1 OF5 and myosin (type \I) antibody CPu had fluorescent averages of 117.96 and 
100.09 respectively, and p-values of 0.01132 and 0.05876. When compared to negative 
controls, CPu fluorescence ieveJs for both the mAb1 OF5 and myosin (type II) antibody groups 
were significant at 24 and 48 hours, while only the values of the mAb10F5 group were 
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significant after 72 hours. One control slice did contain a false positive within the CPu. 
However, this outlier was not used in data analysis. 
Figure 1. Fluorescent microscopy of 
midrostral CPu using Alexa Fluor 
488 and a 1 Ox objective. (A) 
Negative control. 24 hour mAb10F5 
(8) and myosin (type II) antibody (C). 
48 hour mAb10F5 (0) and myosin 
(type II) antibody (E). 72 hour 
mAb10F5 near the CPu border (F) 
and myosin (type II) antibody (G). 
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Fluorescence levels within the rostral CPu were also compared (Table 2). Average 
rostral CPu fluorescence for the uninjected controls was 91.09. Average CPu fluorescence at 
24 hours was 91 .61 for mAb 1 OF5 treated rats and 77.67 for myosin (type II) antibody treated 
rats . At 48 hours, average CPu fluorescence was 85.78 for mAb1 OF5 treated rats and 111.29 
for myosin (type II) antibody treated rats. Average fluorescence at 72 hours was 98.00 for 
mAb 1 OF5 treated rats and 116.74 for myosin (type II) antibody rats . Since no pattern could be 
discerned from the data and images, further analysis was not performed. 
Also in the midrostral CPu, a cloud of fluorescence was observed in the mAb1 OF5 
treated rats usually at 24 hours, and in the myosin (type II) antibody treated rats usually at 48 
hours (Figure 2). This phenomenon was not seen in the uninjected controls . 
Figure 2. In the midrostral CPu, a cloud of fluorescence indicating the 
p resen ce of a nti bod y was obse rved in the mAb 1 0 F 5 treated rats at 24 ho urs 
(left) and in the myosin (type II) antibody treated rats at 48 hours (right). This 
was not observed in the negative controls. 
The hippocampus of both the mAb10F5 and myosin (type II) antibody treated groups 
was negative for all time pOints as compared with the uninjected controls (Figure 3). Data was 
analyzed from fluorescent images taken with a 5x objective as these represented each group at 
every time point (Table 3). However, data for the images taken with the 1 Ox objective which 
were available were also negative. The hippocampus for the 48 and 72 hour mAb10F5, and the 
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24 hour myosin (type 11) antibody treated groups were even significantly negative (p<.05) when 
compared to uninjected controls. 
Figure 3. Fluorescent images 
taken with 5x objective showing the 
negative hippocampus. (A) 
Negative Control, (8) 48 hour 
mAb10F5, (C) 48 hour myosin (type 
II) antibody, (0) 72 hour mAb1 OF5, 
and (E) 72 hour myosin (type II) 
antibody. All time points contained 
&. negative hippocampus region. 
The cortex of rats injected with either mAb10F5 or myosin (type II) antibody was 
negative at all time pOints when compared to controls (Figure 4). Data from images in the same 
area of the midrostral cortex of antibody treated rats was compared to controls (Table 4). 
Values were taken from within the cortex and ignored the blood vessel (see figure 4). The 
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co rte x of the neg ative can tro I g ro up had a nave rag e fl U oresce n ce of 72.70. The mAb 1 0 F 5 
treated group had an average fluorescence in the cortex of 76.39 at 24 hours, 86.16 at 48 
hours, and 52.78 at 72 hours . The myosin (type II) antibody had cortex fluorescence values of 
69.27 at 24 hours, 66.29 at 48 hours, and 69.52 at 72 hours . Neither the mAb10F5 group nor 
the myosin (type II) antibody group was significant for fluorescence in the cortex at any time 
point when compared to negative controls. 
Figure 4. Fluorescent images 
obtained using a 10x objective 
displaying negative cortical region. 
(A) Negative control, (8) 48 hour 
mAb10F5, and (C) 48 hour myosin 
(type II) antibody, (0) 72 hour 
mAb1 OF5, and (E) 72 hour myosin 
(type II) antibody. 
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Discussion 
Results from this study support the hypothesis from in vitro data that group A 
streptococcal antibody mAb10F5 binds in the area of the basal ganglia in the brains of Lewis 
rats . This finding is congruent with the in vitro study done previously in our lab. The mAb10F5 
was found significantly in the CPu but not the hippocampus or cortex as detennined by the 
presence of fluorescence. This suggests that mAb10F5 is an anti-basal ganglia antibody. As 
anti-basal ganglia antibodies have been documented in PANDAS, Tourette syndrome, and 
Sydenham's chorea, a 10F5e antibody could be the culprit in these movement disorders 
(Church et a!. 2004, Rizzo et al. 2006, Singer et al. 2004, Trifiletti et a!. 1999). This means that 
mAb10F5, which recognizes the conserved region of the streptococcal M6 protein , is cross-
reacting with neuronal tissues in an autoimmune fashion. 
Though we did not monitor the rats for changes in motor activity for this study, we can 
hypothesize how a change may occur. The mAb10F5 bound specifically in the CPu, illustrating 
that it most likely works by inhibiting the inhibition of the globus pallidus. Such dysfunction 
would allow the thalamus to send unwanted movement signals to the motor corlices to be 
executed . Since our laboratory has previously observed that mAb10F5 has antiphospholipid 
properties, the streptococcal antibody may be interacting with endothelial or pericyte cells at the 
level of the brain capillaries . Once inside the CPu, an interaction involving components of the 
CPu could promote neurotransmitter release and dysfunction of movement regulation leading to 
movement disorders . 
In the midrostral CPu, mAb1 OF5 treated rats had fluorescence levels significantly (p<.05) 
elevated above negative control values at all three of the time points (24, 48, and 72 hours). 
The cloud of fluorescence, usually visualized at 24 hours, may be the antibody leaking out of the 
capillaries Into the Interstitial fluid and the entrapment of Alexa Fluor In the Interslllicd space. 
Since the fluorescence levels continue to be significantly elevated at 48 hours, the antibody has 
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most likely been taken up into the tissues by this time point. At 72 hours, the antibody remained 
in the tissues of the CPu demonstrated by the presence of fluorescence still significantly above 
negative control values . 
In comparison, the midrostral CPu fluorescence levels of the myosin (type II) antibody 
treated rats were only significantly elevated above controls during the 24 and 48 hour lime 
points. The cloud of antibody as it diffused into the interstitial fluid was usually not seen until the 
48 hour time point. 8y 72 hours the fluorescence levels dropped to an insignificant value. This 
suggests that the myosin (type II) antibody was beginning to be removed from the tissues by 72 
hours. 
Looking at the activities of the antibodies, it can be seen thai both mAb1 OF5 and myosin 
(type II) antibody can pass through the blood-brain-barrier. This tended to happen at 24 hours 
in the mAb10F5 rats, but not until 48 hours in the myosin (type Il) antibody rats. 80th anlibodies 
had very high fluorescence values at 48 hours, showing that the antibodies were predominantly 
in the CPu. At 72 hours, the myosin (type II) antibody was already beginning to be removed 
from the area, while mAb10F5 remained in the CPu. 
The data gathered in the CPu of the rostral quarter was inconclusive. Many of the blood 
vessels within the Lewis rat brain come up past the rostral section into the midrostral section 
making capillary beds denser in the mid rostral region. Therefore, the lack of sufficient data in 
the rostral quarter may not be because mAb1 OF5 is incapable of binding in this area. It may 
simply be that the antibody has more chances to cross the blood-brain-barrier in the midrostral 
region, due to the slower movement of blood through the capillaries, than it does in the rostral 
area. 
Conclusion 
The group A streptococcal M6 antibody, mAb1 OF5, cross reacts with tissues in the based 
ganglia making it an anti-basal ganglia antibody. The presence of the antibody in the CPu 
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suggests that mAbi0F5 is crossing the blood-brain-barrier to bind to these neuronal tissues. 
Such binding could allow mAbi OF5 to disrupt the normal function of the CPu and inhibit the 
inhibition of unwanted movement. This type of autoimmune interaction would implicate 
mAbi0F5 like antibodies as a potential cause of movement disorders such as PANDAS, 
Tourette syndrome, and Sydenham's chorea . Future studies need to analyze patients with 
these disorders for i0F5e antibodies. Also, further insight into the exact mechanism of 
mAbi OF5 action is necessary. 
It was observed that the mAb10F5 diffused out of the capillaries and into the tissues of 
the CPu at 24 hours and remained there through 72 hours. In contrast, myosin (type II} 
antibody did not diffuse into the interstitial fluid until 48 hours, and was beginning to be removed 
from the CPu by 72 hours. Additional time points are necessary to establish the amount of time 
it takes for mAbi0F5 to be removed . Longer animal studies, possibly with increased or multiple 
mAb10F5 doses, would be needed. Future studies would need to be performed to determine if 
neurological symptoms manifest from the presence of the antibody in the brain_ A correlation of 
symptoms with indicators of PANDAS, Tourette syndrome, andlor Sydenham's chorea would 
elucidate which disorders mAb10F5 plays a role in _ 
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Appendix 
Group Fluorescent Levels Average p-value 
Neg. Control 49.472 78.504 84.685 60.981 21.534 81.664 62.807 
24 hour mAblOFS 88.387 115.012 107.113 156.803 147.776 124.018 0.00437 
antimyosin 72.050 107.319 88.038 120.822 87.206 95.087 0.03953 
48 hour mAb.10F5 110.187 134.460 122.819 139.918 153.889 132.255 0.00044 
anti myosin 165.475 161.870 180.212 160.014 100.190 153.552 0.00040 
72 hour mAb10FS 99.047 136.498 118.339 117.961 0.01132 
anti myosin 136.792 94.597 102.791 66.168 100.087 0.05876 
Table 1. Mid rostral CPu fluorescence levels on a scale from 0-255. Obtained from a single 
factor ANOVA, p<.05 values indicate significant binding of the antibody at the time point 
compared to the negative control group. Both the mAb10F5 group and the myosin (type II) 
antibody group had significant fluorescence at 24 and 48 hours, while only the mAb10F5 
group's values were significant at 72 hours. 
Group Fluorescent Levels Average 
Neg. Control 106.558 46.183 69 .145 100.801 111.914 106.139 96.899 91.091 
24 hour mAb10F5 94.277 62.906 58.654 87.520 151.112 95.185 91.609 
antimyosin 36.426 93.204 50.548 133 .955 74.195 77.666 
48 hour rnAb10FS 86.809 86.480 84.050 85.780 
anti myosin 116.817 181.795 120.567 80.708 56.567 111.291 
72 hour mAblOFS 62.708 117.278 121.104 110.453 78.440 97.996 
anti myosin 139.606 104.455 128.943 78.519 132.176 116.740 
Table 2. Rostral CPu fiuorescence levels. Results showed no patterns, making further 
analysis unnecessary. 
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Group Fluorescent levels Average p-value 
Neg. Control 54.377 51.580 50.667 52.208 
24 hour mAb10F5 61.159 50.766 55.963 0.43055 
antimyosin 39.022 39.022 0.02748 
48 hour mAblOF5 46.709 43.302 45.005 0.03310 
anti myosin 50.661 51.146 50.904 0.43526 
72 hour mAb10FS 34,194 34.194 0.01501 
antimyosin 51.580 40.401 46.713 42.487 45.295 0.07418 
Table 3. Fluorescence levels of the hippocampus. Obtained from a single factor ANOVA, 
p>.05 values show that fluorescence levels were not significant when compared to negative 
controls. Those values that are significant (p<.05) only demonstrate that the fluorescence levels 
were significantly negative compared to the negative controls . These results indicate that the 
hippocampus was negative for antibody binding in both the mAb1 OF5 and myosin (type II) 
antibody groups. 
Group Fluorescent levels Average p-value 
Neg. Control 73.380 121.425 54.791 58.769 55.155 72.704 
24 hour mAb10F5 53.164 68.788 107.204 76.385 0.86363 
antimyosin 84.270 54.265 69.268 0.88508 
48 hour mAblOF5 122.109 50.201 86.155 0,65631 
antimyosin 60.072 66.730 45.356 93.002 66.290 0.71387 
72 hour mAblOF5 52.161 60.475 45.697 52.778 0.28929 
anti myosin 71.734 64.899 71.923 69.519 0.85706 
Table 4. Levels of fluorescence in the midrostral cortex. All values were insignificant (p>.05) 
when compared to the negative control group . This indicates that the cortical region was 
negative at all time points for both mAb10F5 and myosin (type \I) antibody. 
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